[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR2824333B1 - Nouveaux polynucleotides et polypeptides de l'ifn alpha 5 - Google Patents

Nouveaux polynucleotides et polypeptides de l'ifn alpha 5

Info

Publication number
FR2824333B1
FR2824333B1 FR0105919A FR0105919A FR2824333B1 FR 2824333 B1 FR2824333 B1 FR 2824333B1 FR 0105919 A FR0105919 A FR 0105919A FR 0105919 A FR0105919 A FR 0105919A FR 2824333 B1 FR2824333 B1 FR 2824333B1
Authority
FR
France
Prior art keywords
polypeptides
ifn alpha
novel polynucleotides
polynucleotides
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0105919A
Other languages
English (en)
Other versions
FR2824333A1 (fr
Inventor
Jean Louis Escary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GenOdyssee SA
Original Assignee
GenOdyssee SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GenOdyssee SA filed Critical GenOdyssee SA
Priority to FR0105919A priority Critical patent/FR2824333B1/fr
Priority to AU2002319176A priority patent/AU2002319176A1/en
Priority to PCT/EP2002/005458 priority patent/WO2003000896A2/fr
Priority to JP2003507279A priority patent/JP2004535196A/ja
Priority to EP02748710A priority patent/EP1383895A2/fr
Publication of FR2824333A1 publication Critical patent/FR2824333A1/fr
Application granted granted Critical
Publication of FR2824333B1 publication Critical patent/FR2824333B1/fr
Priority to US10/698,402 priority patent/US7358333B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
FR0105919A 2001-05-03 2001-05-03 Nouveaux polynucleotides et polypeptides de l'ifn alpha 5 Expired - Fee Related FR2824333B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0105919A FR2824333B1 (fr) 2001-05-03 2001-05-03 Nouveaux polynucleotides et polypeptides de l'ifn alpha 5
AU2002319176A AU2002319176A1 (en) 2001-05-03 2002-05-02 Polynucleotides and polypeptides of the ifnalpha-5 gene
PCT/EP2002/005458 WO2003000896A2 (fr) 2001-05-03 2002-05-02 Nouveaux polynucleotides et polypeptides du gene ifn$g(a)-5
JP2003507279A JP2004535196A (ja) 2001-05-03 2002-05-02 ＩＦＮα−５遺伝子のポリヌクレオチド及びポリペプチド
EP02748710A EP1383895A2 (fr) 2001-05-03 2002-05-02 Nouveaux polynucleotides et polypeptides du gene ifn$g(a)-5
US10/698,402 US7358333B2 (en) 2001-05-03 2003-11-03 Polypeptides of the IFNα-5 gene

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0105919A FR2824333B1 (fr) 2001-05-03 2001-05-03 Nouveaux polynucleotides et polypeptides de l'ifn alpha 5

Publications (2)

Publication Number Publication Date
FR2824333A1 FR2824333A1 (fr) 2002-11-08
FR2824333B1 true FR2824333B1 (fr) 2003-08-08

Family

ID=8862939

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0105919A Expired - Fee Related FR2824333B1 (fr) 2001-05-03 2001-05-03 Nouveaux polynucleotides et polypeptides de l'ifn alpha 5

Country Status (6)

Country Link
US (1) US7358333B2 (fr)
EP (1) EP1383895A2 (fr)
JP (1) JP2004535196A (fr)
AU (1) AU2002319176A1 (fr)
FR (1) FR2824333B1 (fr)
WO (1) WO2003000896A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
FR2822845B1 (fr) * 2001-03-30 2003-12-12 Genodyssee Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
WO2011017160A1 (fr) * 2009-07-28 2011-02-10 Pestka Biomedical Laboratories, Inc. Protéines et gènes d'interférons humains mutant
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas
CN113166261A (zh) 2018-10-11 2021-07-23 印希比股份有限公司 B7h3单域抗体及其治疗性组合物
JP2022504822A (ja) 2018-10-11 2022-01-13 インヒブルクス インコーポレイテッド Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
AU2019356573A1 (en) 2018-10-11 2021-05-27 Inhibrx Biosciences, Inc. PD-1 single domain antibodies and therapeutic compositions thereof
WO2020076992A1 (fr) 2018-10-11 2020-04-16 Inhibrx, Inc. Anticorps à domaine unique 5t4 et leurs compositions thérapeutiques

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341567C (fr) 1980-01-08 2008-02-19 Charles Weissmann Sequences d'adn, ainsi que des molecules d'adn recombinant et des procedes pour synthetiser les polypeptides semblable a l'interferon humain
US4973479A (en) 1982-01-15 1990-11-27 Cetus Corporation Interferon-α61
WO1983002461A1 (fr) 1982-01-19 1983-07-21 Cetus Corp Interferons hybrides de classes multiples
US4966843A (en) 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
JPS6156199A (ja) 1984-08-27 1986-03-20 Shionogi & Co Ltd 新規ヒトインタ−フエロンα類
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
WO1998020165A2 (fr) * 1996-11-06 1998-05-14 Whitehead Institute For Biomedical Research Marqueurs bialleliques
EP1037995A1 (fr) * 1997-12-08 2000-09-27 Genentech, Inc. Interferon-epsilon humain: interferon de type 1
ES2138565B1 (es) * 1998-05-13 2000-08-16 Inst Cientifico Tecnol Navarra Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es.
AU4845699A (en) * 1998-07-28 2000-02-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Interferon alpha hybrids
JP2003511031A (ja) * 1999-10-07 2003-03-25 マキシジェン， インコーポレイテッド ＩＦＮ−αホモログ

Also Published As

Publication number Publication date
FR2824333A1 (fr) 2002-11-08
AU2002319176A1 (en) 2003-01-08
JP2004535196A (ja) 2004-11-25
EP1383895A2 (fr) 2004-01-28
US20040142431A1 (en) 2004-07-22
WO2003000896A3 (fr) 2003-07-17
US7358333B2 (en) 2008-04-15
WO2003000896A2 (fr) 2003-01-03

Similar Documents

Publication Publication Date Title
NO20040246L (no) TACI'er- og BR3-polypeptider og anvendelser derav
FR12C0012I2 (fr) Combinaisons d'herbicides et de phytoprotecteurs
PT1123255E (pt) Coluna de bolhas e sua utilizacao
FR2826011B1 (fr) Nouveaux derives de la 7-oxo-dhea et utilisation cosmetique
DE69619733D1 (de) Bestimmung der kraftfahrradpositionen und orientierungen
MA27126A1 (fr) 3'PROMEDICAMENTS DE 2'-DESOXY- β-L-NUCLEOSIDES
FR14C0007I2 (fr) Remodelage et glycoconjugaison de peptides
FR2823220B1 (fr) Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
DE60233192D1 (de) Hydrophobe und lipophobe zusammensetzung
NO20002691D0 (no) IFNAR 2/IFN kompleks
FR2825102B1 (fr) Nouveaux polynucleotides et polypeptides de l'interferon alpha 14
FR2824333B1 (fr) Nouveaux polynucleotides et polypeptides de l'ifn alpha 5
FR2831732B1 (fr) Fourniture d'images numeriques geolocalisees personnalisees
FR2825716B1 (fr) Nouveaux polynucleotides et polypeptides de l'ifn alpha 7
FR2805461B1 (fr) Nouveaux agents de gommage cutane et nouvelles compositions cosmetiques
ID22326A (id) Struktur montasi sarung garpu
IT1286663B1 (it) Proteina capace di inibire l'attivita' ribosomiale,sua preparazione ed uso come immunoconiugato chimico o ricombinante e sequenza di cdna
MA24411A1 (fr) Muteines de l'obesite
FR2799755B1 (fr) Preparation de chlorure d'alcoylsufonyle perfluore en alpha du soufre
NO20005547D0 (no) Myelinbasiske proteinpeptider og anvendelser derav
EE200000694A (et) Inimese rekombinantse iterferooni beeta-1a (IFN-ß-1a) formulatsioon
AU4587101A (en) Novel human secreted proteins and polynucleotides encoding the same
IS5778A (is) Stökkbrigði af mennskri lifrarbólgu B veiru og notkun hennar
FR2832149B1 (fr) Nouveaux inhibiteurs de l'angiogenese et leur utilisation pharmaceutique et cosmetique
AU2002245311A8 (en) Human protein kinase n-like polypeptide and uses thereof

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20110131